BRPI0708779A2 - derivados de pirrolopirimidina utilizados como inibidores de hsp90 - Google Patents

derivados de pirrolopirimidina utilizados como inibidores de hsp90 Download PDF

Info

Publication number
BRPI0708779A2
BRPI0708779A2 BRPI0708779-9A BRPI0708779A BRPI0708779A2 BR PI0708779 A2 BRPI0708779 A2 BR PI0708779A2 BR PI0708779 A BRPI0708779 A BR PI0708779A BR PI0708779 A2 BRPI0708779 A2 BR PI0708779A2
Authority
BR
Brazil
Prior art keywords
formula
pyrrolo
pyrimidine
phenyl
original document
Prior art date
Application number
BRPI0708779-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Brough Paul
James Drysdale Martin
Gareth Morse Davies Nicholas
Noel Foloppe Nicolas
Stokes Stephan
Original Assignee
Vernalis R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0604944.9A external-priority patent/GB0604944D0/en
Priority claimed from GBGB0617789.3A external-priority patent/GB0617789D0/en
Application filed by Vernalis R & D filed Critical Vernalis R & D
Publication of BRPI0708779A2 publication Critical patent/BRPI0708779A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
BRPI0708779-9A 2006-03-11 2007-03-09 derivados de pirrolopirimidina utilizados como inibidores de hsp90 BRPI0708779A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0604944.9 2006-03-11
GBGB0604944.9A GB0604944D0 (en) 2006-03-11 2006-03-11 Pyrrolopyrimidine compounds
GB0617789.3 2006-09-09
GBGB0617789.3A GB0617789D0 (en) 2006-09-09 2006-09-09 Pyrrolopyrimidine compounds
PCT/GB2007/000831 WO2007104944A1 (en) 2006-03-11 2007-03-09 Pyrrolopyrimidine derivatives used as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0708779A2 true BRPI0708779A2 (pt) 2011-06-14

Family

ID=38038718

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708779-9A BRPI0708779A2 (pt) 2006-03-11 2007-03-09 derivados de pirrolopirimidina utilizados como inibidores de hsp90

Country Status (11)

Country Link
US (1) US20090163490A1 (enExample)
EP (1) EP2007767B1 (enExample)
JP (1) JP2009533323A (enExample)
KR (1) KR20090007319A (enExample)
AT (1) ATE531718T1 (enExample)
AU (1) AU2007226344A1 (enExample)
BR (1) BRPI0708779A2 (enExample)
CA (1) CA2645343A1 (enExample)
EA (1) EA200801968A1 (enExample)
MX (1) MX2008011559A (enExample)
WO (1) WO2007104944A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
GB0718433D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN103298817A (zh) 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3154547B1 (en) 2014-06-13 2023-06-07 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
SG10202106949XA (en) * 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DE60236458D1 (de) * 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável

Also Published As

Publication number Publication date
JP2009533323A (ja) 2009-09-17
CA2645343A1 (en) 2007-09-20
ATE531718T1 (de) 2011-11-15
MX2008011559A (es) 2008-11-25
EP2007767B1 (en) 2011-11-02
EP2007767A1 (en) 2008-12-31
EA200801968A1 (ru) 2009-02-27
US20090163490A1 (en) 2009-06-25
KR20090007319A (ko) 2009-01-16
WO2007104944A1 (en) 2007-09-20
AU2007226344A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
EP1675861B1 (en) Pyrimidothiophene compounds
EP2007767B1 (en) Pyrrolopyrimidine derivatives used as hsp90 inhibitors
EP1567151B1 (en) 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
US7728016B2 (en) Substituted 5-membered ring compounds and their use
US20110034457A1 (en) Pyridothiophene Compounds
JP4891904B2 (ja) ピリミドチオフェン化合物
US20090181989A1 (en) Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer
HUT70832A (en) 1,2,3,4-tetrahydro-pyrazo [5,1-c][1,2,4] triazines, pharmaceutical compositions containing them and process for preparing them
US20100010037A1 (en) 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
WO2006090094A1 (en) Pyrimidothiophene compounds for use as hsp90 inhibitors
CN101432287A (zh) 用作hsp90抑制剂的吡咯并嘧啶衍生物
EP1851228B1 (en) Pyrimidothiophene compounds having hsp90 inhibitory activity
MXPA06002118A (en) Pyrimidothiophene compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2225 DE 27/08/2013.